Uncategorized
Sustained delivery of ranibizumab for AMD may reduce treatment burden
SAN FRANCISCO — Sustained delivery of ranibizumab with a port delivery system in patients with neovascular age-related macular degeneration has the potential to improve visual outcomes and reduce the treatment burden associated with anti-VEGF injections, according to a scientific poster presented at the American Society of Retina Specialists meeting. LADDER is a phase 2 study evaluating dosing and functional outcomes with sustained delivery of Lucentis (ranibizumab, Genentech) via the ranibizumab port delivery system (RPDS), which aims to provide longer treatment intervals than any currently available therapy, study co-author Richard F. (Read more...)